Table 1. Clinical and pathological features of HCC patients (n=136) with correlation to PDGFRA expression.
| PDGFRA positive | PDGFRA negative | |
|---|---|---|
| Immunopositivity | 66.18% (90/136) | 33.82% (46/136) |
| Age (years) (mean) | 63.09 (NS) | 60.74 (NS) |
| Gender | ||
| Male | 68.89% (62/90; NS) | 71.74% (33/46; NS) |
| Female | 31.11% (28/90; NS) | 28.26% (13/46; NS) |
| Etiology | ||
| HBV | 5.56% (5/90; NS) | 10.87% (5/46; NS) |
| HCV | 24.44% (22/90; NS) | 32.61% (15/46; NS) |
| HBV+HCV | 1.11% (1/90; NS) | 6.52% (3/46; NS) |
| ALD | 13.33% (12/90; NS) | 17.39% (8/46; NS) |
| ALD+viral infection | 2.22% (2/90; NS) | 0% (0/46; NS) |
| Other | 36.66% (33/90; NS) | 19.57% (9/46; NS) |
| Unknown | 16.67% (15/90; NS) | 13.04% (6/46; NS) |
| Microvascular invasion | 78.89% (71/90; P<0.001) | 19.57% (9/46; NS) |
| Metastasis | 68.18% (45/66; P<0.001) | 20.59% (7/34; NS) |
| Tumor size (cm; mean) | 5.75 (P<0.05) | 3.83 |
| K19 expression | 14.44% (13/90; P<0.001) | 0% (0/46; NS) |
| early HCCs | 3.33% (3/90; NS) | 26.09% (12/46; NS) |
| Differentiation grade | ||
| Well | 28.89% (26/90) | 6.52% (3/46) |
| Moderate | 44.44% (40/90) | 32.61% (15/46) |
| Poorly | 26.67% (24/90) | 60.87% (28/46) |
| Cirrhosis | ||
| No | 33.33% (30/90; NS) | 15.22% (7/46; NS) |
| Yes | 65.56% (59/90; NS) | 82.61% (38/46; NS) |
| Unknown | 1.11% (1/90; NS) | 2.17% (1/46; NS) |
Abbreviations: ALD, alcoholic liver disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NS, not significant; PDGFRA, platelet-derived growth factor receptor α. Bold values indicate significance.